Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Downstream Processing01:29

Downstream Processing

Downstream processing begins once fermentation is complete and involves a series of steps to recover and purify products such as acids, vitamins, antibiotics, or proteins.Cell HarvestingFor example, for intracellular protein-based products, the first step is harvesting the cells. This is typically achieved using centrifugation or filtration to separate the cells from the liquid phase.Cell Disruption for Intracellular ProductsIf the target product is intracellular, the harvested cells must be...
Clinically Relevant Drug Product Specifications: Methods of Establishment01:29

Clinically Relevant Drug Product Specifications: Methods of Establishment

Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A comparison of network sampling designs for a hidden population of drug users: Random walk vs. respondent-driven sampling.

Social science research·2017
Same author

Gauging patient safety programs.

Journal of allied health·2013
Same author

An overview of FDA regulatory requirements for new medical devices.

Expert opinion on medical diagnostics·2013
Same author

The pathology of alcohol use and abuse.

Clinical laboratory science : journal of the American Society for Medical Technology·2013
Same author

Patient safety and quality improvement: a policy assessment.

Clinical laboratory science : journal of the American Society for Medical Technology·2010
Same author

Direct-to-consumer advertising: its effects on stakeholders.

Journal of allied health·2008
Same journal

Could anticholinergics accelerate ALS progression? A critical perspective on drug safety and disease vulnerability.

Expert opinion on drug safety·2026
Same journal

Safety profile of teprotumumab-trbw, the first and only FDA-approved treatment for thyroid-associated ophthalmopathy.

Expert opinion on drug safety·2026
Same journal

A systematic review and meta-analysis of safety and efficacy parameters of sotatercept in the therapy of pulmonary arterial hypertension.

Expert opinion on drug safety·2026
Same journal

Tirzepatide data: safety first is safety always!

Expert opinion on drug safety·2026
Same journal

An update on the safety of biologics for the treatment of psoriasis.

Expert opinion on drug safety·2026
Same journal

Recent advances in trastuzumab and its antibody-drug conjugates-related liver injury.

Expert opinion on drug safety·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
05:46

Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

Published on: August 1, 2018

E-detailing: information technology applied to pharmaceutical detailing.

Isaac D Montoya

    Expert Opinion on Drug Safety
    |November 6, 2008
    PubMed
    Summary
    This summary is machine-generated.

    Electronic detailing (e-detailing) leverages information technology to enhance pharmaceutical marketing, offering cost savings and improved physician access. While widely adopted, it currently supplements, rather than replaces, traditional detailing methods.

    More Related Videos

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
    07:00

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

    Published on: August 11, 2017

    Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
    11:56

    Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

    Published on: October 25, 2013

    Related Experiment Videos

    Last Updated: Jun 28, 2026

    Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation
    05:46

    Identification of Pharmaceuticals in The Aquatic Environment Using HPLC-ESI-Q-TOF-MS and Elimination of Erythromycin Through Photo-Induced Degradation

    Published on: August 1, 2018

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface
    07:00

    Failure of Cleaning Verification in Pharmaceutical Industry Due to Uncleanliness of Stainless Steel Surface

    Published on: August 11, 2017

    Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
    11:56

    Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection

    Published on: October 25, 2013

    Area of Science:

    • Pharmaceutical Marketing
    • Health Informatics
    • Medical Communications

    Background:

    • E-detailing utilizes information technology for pharmaceutical sales and marketing.
    • It offers benefits such as maximized sales force time, reduced costs, and increased physician prescribing.
    • Initially launched in the US in 1996, e-detailing has gained global adoption.

    Discussion:

    • The paper reviews e-detailing literature and physician feedback.
    • E-detailing provides advantages like reduced marketing expenses and enhanced physician accessibility.
    • Physicians appreciate the convenience of accessing product information on their own schedule.

    Key Insights:

    • E-detailing is rapidly growing in pharmaceutical marketing.
    • It offers benefits comparable to face-to-face detailing, including convenience for physicians.
    • Drug safety considerations in e-detailing require further investigation.

    Outlook:

    • E-detailing is expected to continue its growth trajectory in pharmaceutical promotion.
    • Further research is needed to address the drug safety aspects of e-detailing.
    • E-detailing is currently positioned as a complementary tool to traditional pharmaceutical detailing.